Data from selected patients in the RUBY trial demonstrate improvements in QoL domains over the course of treatment, as well

Antitumor responses were comparable to those previously reported for a larger population of advanced melanoma patients. This session was st

Some safety and efficacy data of novel immunotherapy agents are encouraging, but additional research is necessary to identify biomarkers and

This late breaking poster was presented on st October 21 at the ESMO Congress at Madrid. Although RAI is commonly

This late breaking presentation was presented on st October 21 at the ESMO Congress at Madrid. The TGCA data suggest

This late breaking presentation was presented on st October 21 at the ESMO Congress at Madrid. Androgen deprivation therapy (ADT)

Sunday, October 22nd 2023, Madrid, Spain :  Patients with this aggressive disease may benefit from neoadjuvant, perioperative, targeted, and combined

Adding immunotherapy to the standard of care demonstrates efficacy versus placebo and is confirmed to change clinical practice for this